ArticleScientific reports2026
Burden of incident cardiovascular events in giant cell arteritis using data from a nationwide French cohort.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA) is one of the most common adult vasculitis. As large-scale studies on cardiovascular events in GCA are missing in France, our study examine their incidence using the French national medico-administrative health database. We included patients hospitalized for GCA between January 2013 and December 2022 who received an initial prescription of corticosteroids ≥ 1000 mg over 40 days within one year of the hospitalization. Each patient was matched with three controls by age, sex, and residence. Cardiovascular events and mortality were compared using a multivariate Cox model, adjusting for hypertension, diabetes, dyslipidemia, obesity, sleep apnoea syndrome, chronic kidney disease, and prior cardiovascular conditions. A total of 12,955 GCA patients (67% female) and 33,685 controls were analyzed. Baseline cardiovascular risk factors were more prevalent in patients with GCA. Patients with GCA had a significantly increased risk of all-cause mortality (HR: 1.21 [1.15-1.27]), and major cardiovascular events (1.51 [1.41-1.62]), including myocardial infarction (1.58 [1.36-1.85]), stroke (1.29 [1.14-1.47]), and heart failure (1.41 [1.30-1.52]). A better screening and management of cardiovascular factors could improve overall outcomes in GCA patients. Further studies are needed to determine the impact of treatment strategies, and to better identify at-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.